DK1229909T3 - Transdermal indgivelse af lasofoxifen - Google Patents
Transdermal indgivelse af lasofoxifenInfo
- Publication number
 - DK1229909T3 DK1229909T3 DK01939751T DK01939751T DK1229909T3 DK 1229909 T3 DK1229909 T3 DK 1229909T3 DK 01939751 T DK01939751 T DK 01939751T DK 01939751 T DK01939751 T DK 01939751T DK 1229909 T3 DK1229909 T3 DK 1229909T3
 - Authority
 - DK
 - Denmark
 - Prior art keywords
 - devices
 - lasofoxifene
 - carrier vehicle
 - reservoir
 - drug
 - Prior art date
 
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title abstract 5
 - 229960002367 lasofoxifene Drugs 0.000 title abstract 5
 - 239000000203 mixture Substances 0.000 abstract 3
 - 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract 2
 - 229940079593 drug Drugs 0.000 abstract 2
 - 239000003814 drug Substances 0.000 abstract 2
 - 238000000034 method Methods 0.000 abstract 2
 - 150000003839 salts Chemical class 0.000 abstract 2
 - 206010065687 Bone loss Diseases 0.000 abstract 1
 - 206010006187 Breast cancer Diseases 0.000 abstract 1
 - 208000026310 Breast neoplasm Diseases 0.000 abstract 1
 - 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
 - 201000009273 Endometriosis Diseases 0.000 abstract 1
 - 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 abstract 1
 - 208000008589 Obesity Diseases 0.000 abstract 1
 - 208000025844 Prostatic disease Diseases 0.000 abstract 1
 - 239000000853 adhesive Substances 0.000 abstract 1
 - 230000001070 adhesive effect Effects 0.000 abstract 1
 - 150000001875 compounds Chemical class 0.000 abstract 1
 - 239000003623 enhancer Substances 0.000 abstract 1
 - 239000012530 fluid Substances 0.000 abstract 1
 - 238000009472 formulation Methods 0.000 abstract 1
 - 102000011941 human estrogen receptor alpha Human genes 0.000 abstract 1
 - 239000007788 liquid Substances 0.000 abstract 1
 - 239000011159 matrix material Substances 0.000 abstract 1
 - 235000020824 obesity Nutrition 0.000 abstract 1
 - 230000007170 pathology Effects 0.000 abstract 1
 - 230000002093 peripheral effect Effects 0.000 abstract 1
 - 239000008194 pharmaceutical composition Substances 0.000 abstract 1
 - 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
 - -1 polymeric reservoir Substances 0.000 abstract 1
 - 230000037317 transdermal delivery Effects 0.000 abstract 1
 
Classifications
- 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
 - A61K9/00—Medicinal preparations characterised by special physical form
 - A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
 - A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
 - A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
 - A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
 - A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
 - A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
 - A61K9/7061—Polyacrylates
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
 - A61K31/00—Medicinal preparations containing organic active ingredients
 - A61K31/33—Heterocyclic compounds
 - A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
 - A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
 - A61K9/00—Medicinal preparations characterised by special physical form
 - A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
 - A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
 - A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
 - A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P13/00—Drugs for disorders of the urinary system
 - A61P13/08—Drugs for disorders of the urinary system of the prostate
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P19/00—Drugs for skeletal disorders
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P19/00—Drugs for skeletal disorders
 - A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
 - A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P3/00—Drugs for disorders of the metabolism
 - A61P3/04—Anorexiants; Antiobesity agents
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P35/00—Antineoplastic agents
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P5/00—Drugs for disorders of the endocrine system
 - A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
 - A61P5/30—Oestrogens
 
 - 
        
- A—HUMAN NECESSITIES
 - A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
 - A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
 - A61P9/00—Drugs for disorders of the cardiovascular system
 
 
Landscapes
- Health & Medical Sciences (AREA)
 - Engineering & Computer Science (AREA)
 - Bioinformatics & Cheminformatics (AREA)
 - Life Sciences & Earth Sciences (AREA)
 - Veterinary Medicine (AREA)
 - Chemical & Material Sciences (AREA)
 - Public Health (AREA)
 - Medicinal Chemistry (AREA)
 - General Health & Medical Sciences (AREA)
 - Animal Behavior & Ethology (AREA)
 - Pharmacology & Pharmacy (AREA)
 - Dermatology (AREA)
 - General Chemical & Material Sciences (AREA)
 - Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
 - Chemical Kinetics & Catalysis (AREA)
 - Organic Chemistry (AREA)
 - Epidemiology (AREA)
 - Physical Education & Sports Medicine (AREA)
 - Diabetes (AREA)
 - Rheumatology (AREA)
 - Orthopedic Medicine & Surgery (AREA)
 - Cardiology (AREA)
 - Obesity (AREA)
 - Hematology (AREA)
 - Urology & Nephrology (AREA)
 - Child & Adolescent Psychology (AREA)
 - Heart & Thoracic Surgery (AREA)
 - Endocrinology (AREA)
 - Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
 - Medicinal Preparation (AREA)
 - Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
 
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| US20878900P | 2000-06-01 | 2000-06-01 | |
| PCT/US2001/017567 WO2001091724A2 (en) | 2000-06-01 | 2001-05-31 | Transdermal delivery of lasofoxifene | 
Publications (1)
| Publication Number | Publication Date | 
|---|---|
| DK1229909T3 true DK1229909T3 (da) | 2004-03-15 | 
Family
ID=22776068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| DK01939751T DK1229909T3 (da) | 2000-06-01 | 2001-05-31 | Transdermal indgivelse af lasofoxifen | 
Country Status (24)
| Country | Link | 
|---|---|
| US (1) | US20020037311A1 (cs) | 
| EP (1) | EP1229909B1 (cs) | 
| JP (1) | JP2003534368A (cs) | 
| KR (1) | KR100795870B1 (cs) | 
| CN (1) | CN1400897A (cs) | 
| AT (1) | ATE253910T1 (cs) | 
| AU (2) | AU785199B2 (cs) | 
| BR (1) | BR0106680A (cs) | 
| CA (1) | CA2380769A1 (cs) | 
| CZ (1) | CZ2002488A3 (cs) | 
| DE (1) | DE60101206T2 (cs) | 
| DK (1) | DK1229909T3 (cs) | 
| ES (1) | ES2210168T3 (cs) | 
| HK (1) | HK1052472A1 (cs) | 
| HU (1) | HUP0202592A3 (cs) | 
| IL (2) | IL147640A0 (cs) | 
| MX (1) | MXPA02001152A (cs) | 
| NZ (1) | NZ516582A (cs) | 
| PL (1) | PL201222B1 (cs) | 
| PT (1) | PT1229909E (cs) | 
| RU (1) | RU2328276C2 (cs) | 
| TR (1) | TR200400241T4 (cs) | 
| WO (1) | WO2001091724A2 (cs) | 
| ZA (1) | ZA200200519B (cs) | 
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US7564908B2 (en) * | 2004-09-23 | 2009-07-21 | Motorola, Inc. | Method and apparatus for encryption of over-the-air communications in a wireless communication system | 
| US7804912B2 (en) * | 2004-09-23 | 2010-09-28 | Motorola, Inc. | Method and apparatus for encryption of over-the-air communications in a wireless communication system | 
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular | 
| FR2905601A1 (fr) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques. | 
| WO2009009651A1 (en) * | 2007-07-10 | 2009-01-15 | Agile Therapeutics, Inc. | Dermal delivery device with ultrasonic weld | 
| NZ582565A (en) | 2007-07-10 | 2012-07-27 | Agile Therapeutics Inc | Dermal delivery device with in situ seal | 
| WO2013102207A1 (en) * | 2011-12-30 | 2013-07-04 | Rosscreening, Inc. | Estrogen receptor modulators for reducing body weight | 
| CN103751138A (zh) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法 | 
| CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | 王志刚 | 一种酒石酸拉索昔芬分散片及其制备方法 | 
| CN103830207A (zh) * | 2014-03-14 | 2014-06-04 | 崔书豪 | 一种酒石酸拉索昔芬贴膏剂 | 
| US10737082B2 (en) * | 2015-07-24 | 2020-08-11 | Sorrento Therapeutics, Inc. | Methods for lymphatic delivery of active agents | 
| CA2991455C (en) | 2015-07-24 | 2023-10-10 | Kimberly-Clark Worldwide, Inc. | Methods for better delivery of active agents to tumors | 
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 
| US5122383A (en) * | 1991-05-17 | 1992-06-16 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers | 
| CA2208132A1 (en) * | 1994-12-21 | 1996-06-27 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc | 
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | 
| IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists | 
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis | 
| US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture | 
| US6034102A (en) * | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment | 
| US6203817B1 (en) * | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery | 
| CO5170459A1 (es) * | 1999-06-01 | 2002-06-27 | Pfizer Prod Inc | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos | 
- 
        2001
        
- 2001-05-31 BR BR0106680-3A patent/BR0106680A/pt not_active Application Discontinuation
 - 2001-05-31 CA CA002380769A patent/CA2380769A1/en not_active Abandoned
 - 2001-05-31 AT AT01939751T patent/ATE253910T1/de not_active IP Right Cessation
 - 2001-05-31 KR KR1020027001424A patent/KR100795870B1/ko not_active Expired - Fee Related
 - 2001-05-31 NZ NZ516582A patent/NZ516582A/en active IP Right Revival
 - 2001-05-31 CN CN01801561A patent/CN1400897A/zh active Pending
 - 2001-05-31 PT PT01939751T patent/PT1229909E/pt unknown
 - 2001-05-31 TR TR2004/00241T patent/TR200400241T4/xx unknown
 - 2001-05-31 RU RU2002105378/15A patent/RU2328276C2/ru not_active IP Right Cessation
 - 2001-05-31 IL IL14764001A patent/IL147640A0/xx active IP Right Grant
 - 2001-05-31 PL PL354628A patent/PL201222B1/pl not_active IP Right Cessation
 - 2001-05-31 JP JP2001587740A patent/JP2003534368A/ja active Pending
 - 2001-05-31 HU HU0202592A patent/HUP0202592A3/hu unknown
 - 2001-05-31 CZ CZ2002488A patent/CZ2002488A3/cs unknown
 - 2001-05-31 AU AU65235/01A patent/AU785199B2/en not_active Ceased
 - 2001-05-31 ES ES01939751T patent/ES2210168T3/es not_active Expired - Lifetime
 - 2001-05-31 DK DK01939751T patent/DK1229909T3/da active
 - 2001-05-31 MX MXPA02001152A patent/MXPA02001152A/es unknown
 - 2001-05-31 US US09/871,318 patent/US20020037311A1/en not_active Abandoned
 - 2001-05-31 DE DE60101206T patent/DE60101206T2/de not_active Expired - Fee Related
 - 2001-05-31 WO PCT/US2001/017567 patent/WO2001091724A2/en not_active Application Discontinuation
 - 2001-05-31 HK HK03104920.4A patent/HK1052472A1/zh unknown
 - 2001-05-31 EP EP01939751A patent/EP1229909B1/en not_active Expired - Lifetime
 
 - 
        2002
        
- 2002-01-15 IL IL147640A patent/IL147640A/en not_active IP Right Cessation
 - 2002-01-21 ZA ZA200200519A patent/ZA200200519B/en unknown
 
 - 
        2007
        
- 2007-02-01 AU AU2007200426A patent/AU2007200426A1/en not_active Abandoned
 
 
Also Published As
| Publication number | Publication date | 
|---|---|
| AU2007200426A1 (en) | 2007-02-22 | 
| WO2001091724A2 (en) | 2001-12-06 | 
| HUP0202592A3 (en) | 2003-07-28 | 
| CZ2002488A3 (cs) | 2002-06-12 | 
| KR20030025219A (ko) | 2003-03-28 | 
| RU2002105378A (ru) | 2003-11-10 | 
| TR200400241T4 (tr) | 2004-04-21 | 
| ES2210168T3 (es) | 2004-07-01 | 
| AU785199B2 (en) | 2006-11-02 | 
| CA2380769A1 (en) | 2001-12-06 | 
| HUP0202592A2 (hu) | 2002-12-28 | 
| WO2001091724A3 (en) | 2002-05-30 | 
| BR0106680A (pt) | 2002-04-30 | 
| CN1400897A (zh) | 2003-03-05 | 
| EP1229909A2 (en) | 2002-08-14 | 
| ZA200200519B (en) | 2003-04-22 | 
| DE60101206T2 (de) | 2004-09-02 | 
| US20020037311A1 (en) | 2002-03-28 | 
| EP1229909B1 (en) | 2003-11-12 | 
| PL354628A1 (en) | 2004-02-09 | 
| NZ516582A (en) | 2004-08-27 | 
| IL147640A0 (en) | 2002-08-14 | 
| HK1052472A1 (zh) | 2003-09-19 | 
| ATE253910T1 (de) | 2003-11-15 | 
| RU2328276C2 (ru) | 2008-07-10 | 
| JP2003534368A (ja) | 2003-11-18 | 
| IL147640A (en) | 2007-03-08 | 
| MXPA02001152A (es) | 2002-08-20 | 
| PL201222B1 (pl) | 2009-03-31 | 
| AU6523501A (en) | 2001-12-11 | 
| PT1229909E (pt) | 2004-04-30 | 
| KR100795870B1 (ko) | 2008-01-21 | 
| DE60101206D1 (de) | 2003-12-18 | 
Similar Documents
| Publication | Publication Date | Title | 
|---|---|---|
| US10709669B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
| DE60023520D1 (de) | Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung | |
| ES2733812T3 (es) | Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos | |
| WO2004052336A3 (en) | High viscosity liquid controlled delivery system and medical or surgical device | |
| DK1229909T3 (da) | Transdermal indgivelse af lasofoxifen | |
| RU2003128642A (ru) | Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона | |
| ATE302598T1 (de) | Transdermale vorrichtung zur arzneistoffverabreichung mit einem polyurethanwirkstoffreservoir | |
| DE69326461D1 (de) | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung | |
| US20010033858A1 (en) | Transdermal drug patch | |
| DE602005011653D1 (de) | Medizinprodukt mit gewebeabhängiger arzneimittelelution | |
| FR2727015B1 (fr) | Compositions pharmaceutiques liquides a base d'ondansetron | |
| PT1047409E (pt) | Tts contendo um antioxidante | |
| ES2962896T3 (es) | Parche que contiene rotigotina | |
| TW200514590A (en) | Hydrophilic adhesives for delivery of herbal medicines | |
| AU2003215657A1 (en) | Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion. | |
| US9056060B2 (en) | Non-reactive adhesive useful in transdermal drug delivery system | |
| JP4430120B2 (ja) | 抗真菌症用貼付剤 | |
| NZ332746A (en) | Transdermal propentofylline compositions for the treatment of Alzheimer's disease | |
| MXPA02009103A (es) | Sistema terapeutico transdermal para la administracion de lerisetron. | |
| MY129063A (en) | Transdermal delivery of lasofoxifene | |
| EA200601089A1 (ru) | Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение | |
| WO2024189202A1 (en) | Medical patch comprising capsaicin | |
| CA3232272A1 (en) | Transdermal therapeutic system for the transdermal administration of tizanidine | |
| JP2009242424A (ja) | 抗真菌症用貼付剤 | |
| FR2806625B1 (fr) | Dispositif matriciel pour l'administration transdermique de rilmenidine et son procede de preparation |